Maynard Um
-
-
-
-
-
-
-
Harrow Health (HROW) PT Lowered to $88 at Cantor Fitzgerald
-
-
-
-
-
-
-
William Blair Reiterates Outperform Rating on Harrow Health (HROW): "We believe the long-term growth outlook is attractive"
-
-
-
-
-
-
-
Harrow launches patient access program for ophthalmic portfolio
-
-
-
-
-
-
-
Harrow secures exclusive US rights to Samsung Bioepis eye biosimilars
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Harrow Health (HROW)
-
-
-
-
-
-
-
Harrow Health (HROW) Misses Q3 EPS by 7c
-
-
-
-
-
-
-
Harrow Health (HROW) PT Raised to $30 at Craig-Hallum
-
435,836 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

